2006
DOI: 10.1002/cncr.21824
|View full text |Cite
|
Sign up to set email alerts
|

Economic burden associated with breast cancer recurrence

Abstract: Compared with the West, the overall incidence of lymphoid neoplasms is lower, and the subtype distribution is distinct in Asia. To comprehensively investigate the subtype distribution with the age and sex factors, and temporal changes of subtype proportions, we re‐assessed all patients with lymphoid neoplasms diagnosed at a large oncology service in the Republic of Korea from 1989 to 2008 using the World Health Organization classifications. Of the total 5,318 patients, 66.9% had mature B‐cell neoplasms, 12.5% … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
19
0

Year Published

2007
2007
2022
2022

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 56 publications
(19 citation statements)
references
References 44 publications
0
19
0
Order By: Relevance
“…Moreover, breast cancer can be particularly burdensome due to its sequelae. Management of breast cancer complications such as lymphedema 25 and recurrence 26 have been associated with an increase in economic costs and burden. Similarly, chemotherapy treatment is a predictor of greater financial problems after treatment has ended 27,28 .…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, breast cancer can be particularly burdensome due to its sequelae. Management of breast cancer complications such as lymphedema 25 and recurrence 26 have been associated with an increase in economic costs and burden. Similarly, chemotherapy treatment is a predictor of greater financial problems after treatment has ended 27,28 .…”
Section: Discussionmentioning
confidence: 99%
“…In addition, there was a significantly higher risk of breast cancer-related death for women with distant compared with locoregional recurrences (HR, 3.6, P \ 0.001). Distant recurrence events are also associated with substantially higher healthcare costs compared with locoregional or contralateral recurrences [20]. Adjuvant therapies that reduce the risk for distant, compared with locoregional or contralateral recurrences, are therefore likely to offer the most benefit in terms of survival.…”
Section: Discussionmentioning
confidence: 99%
“…However, costly disease recurrences still occur [2], and tamoxifen is also associated with significant safety concerns such as potentially fatal thromboembolic events and endometrial cancer [3].…”
Section: Introductionmentioning
confidence: 99%